Cholesterol care | New York
Lerochol is the brand name for lerodalcibep-liga, a PCSK9-binding protein approved in December 2025 for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. The labeled dose is 300 mg under the skin once monthly. Patients or caregivers may self-inject after training. The manufacturer announced its U.S. commercial launch on May 11, 2026.
Lerochol is FDA approved and commercially launched in the United States. Its prescribing information was issued in December 2025, and the official launch announcement is dated May 11, 2026. This page describes evaluation and care coordination. A prescription, coverage, dispensing, teaching visit, or administration is never automatic.
The current label indicates Lerochol as an adjunct to diet and exercise to reduce LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.
The visit should establish the patient's LDL level and goal, cardiovascular and family history, prior and current treatment, adherence, allergies, pregnancy or lactation considerations, and whether a monthly self-injection fits the care plan.
The labeled dose is 300 mg by subcutaneous injection once monthly. The patient or caregiver should receive training before self-administration with the prescribed device.
A treatment plan should define lipid reassessment and review injection-site reactions, hypersensitivity, technique, storage, adherence, and response. The full label should guide missed-dose and handling questions.
A brand name is not enough to determine whether treatment is appropriate. The clinician must connect the label to the patient's diagnoses, current medicines, prior treatment, laboratory results, preferences, and coverage.
The visit should establish the patient's LDL level and goal, cardiovascular and family history, prior and current treatment, adherence, allergies, pregnancy or lactation considerations, and whether a monthly self-injection fits the care plan.
A treatment plan should define lipid reassessment and review injection-site reactions, hypersensitivity, technique, storage, adherence, and response. The full label should guide missed-dose and handling questions.
Nao Medical must confirm prescribing, coverage, dispensing, storage counseling, device teaching, and follow-up before offering this pathway. The default administration model is patient or caregiver self-injection after training.
A commercial launch does not establish Nao Medical prescribing, payer, dispensing, or teaching readiness. The page supports evaluation and coordination only until those workflows are approved.
An evaluation may lead to another medicine, more testing, a referral, or no medication change.
The health plan and dispensing pharmacy make coverage and fulfillment decisions. Prior authorization may be required.
The clinic cards below show places to start an evaluation. They do not prove that a product is stocked, dispensed, taught, or administered at that site.
The sequence protects safety and keeps a product request from bypassing diagnosis, records, monitoring, access, or referral needs.
Bring recent lipid results, a current medication and supplement list, prior reactions, relevant diagnoses, and family history when available.
The clinician reviews the reason for treatment, prior response, safety considerations, adherence barriers, and the role of lifestyle support.
The plan may include repeat or additional testing, a medication change, teaching, prior-authorization work, specialist coordination, or continued monitoring.
The care team confirms how results and symptoms will be reviewed. Product supply or administration is arranged only after operational capability is verified.
Choose a nearby Nao Medical clinic as a starting point for evaluation or care coordination.
Capability boundary: these location cards do not establish that a medicine, device, laboratory test, injection, or specialty workflow is available at every site. Confirm the exact service before travel.
Bronx
932 E 174th St, Bronx, NY 10460
A place to begin evaluation and care coordination near West Farms, Crotona Park East, and nearby Bronx neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Queens
37-15 23rd Ave, Astoria, NY 11105
A place to begin evaluation and care coordination near Astoria, Ditmars, East Elmhurst, and nearby Queens neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Bronx
2063A Bartow Ave, Bronx, NY 10475
A place to begin evaluation and care coordination near Co-op City, Pelham Bay, Baychester, and nearby Bronx neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Brooklyn
341 Eastern Pkwy, Brooklyn, NY 11216
A place to begin evaluation and care coordination near Crown Heights, Prospect Heights, and nearby Brooklyn neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Long Island
232 W Old Country Rd, Hicksville, NY 11801
A place to begin evaluation and care coordination near Hicksville, Plainview, Bethpage, and nearby Nassau County communities. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Queens
80-10 Northern Blvd, Jackson Heights, NY 11372
A place to begin evaluation and care coordination near Jackson Heights, Elmhurst, Corona, and nearby Queens neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Queens
90-18 Sutphin Blvd, Jamaica, NY 11435
A place to begin evaluation and care coordination near Jamaica, Briarwood, Richmond Hill, and nearby Queens neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Queens
30-07 36th Ave, Astoria, NY 11106
A place to begin evaluation and care coordination near Long Island City, Astoria, Sunnyside, and nearby Queens neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Long Island
135 Mineola Blvd, Mineola, NY 11501
A place to begin evaluation and care coordination near Mineola, Garden City, Westbury, and nearby Nassau County communities. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Manhattan
259 1st Ave, New York, NY 10003
A place to begin evaluation and care coordination near StuyTown, the East Village, Gramercy, and nearby Manhattan neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Brooklyn
308 Graham Ave, Brooklyn, NY 11211
A place to begin evaluation and care coordination near Williamsburg, Greenpoint, Bushwick, and nearby Brooklyn neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Use these focused pages to compare options, prepare for an evaluation, and connect medication questions with broader care.
Explore broader cardiovascular prevention and cholesterol care at Nao Medical.
Compare established self-injection schedules and label differences.
Review another PCSK9 antibody and its distinct dosing options.
Compare clinician administration with monthly self-injection.
Review inherited high cholesterol before focusing on one medicine.
Answers reflect the current official sources and the limited evaluation-and-coordination scope described on this page.
These sources support product identity, approval, current labeling, availability, and clinical boundaries. They do not prove Nao Medical site capability or health-plan coverage.
FDA-approved identity, indication, monthly dose, self-administration, and safety information.
Open official sourceOfficial U.S. commercial launch date and access program context.
Open official sourceCurrent risk assessment, LDL-lowering treatment, Lp(a), ApoB, and monitoring guidance.
Open official sourcePatient-selection principles and the roles of Lp(a), ApoB, and nonstatin therapies.
Open official sourceSource and label check completed August 1, 2026. Named clinical and operations review is still pending.
General information only. This page is not medical advice and does not replace diagnosis, treatment, or guidance from a licensed clinician.
Content was updated August 1, 2026 from the sources cited on this page. Medical guidance, prescribing information, medication availability, and insurance rules can change. A licensed clinician must confirm current information and determine each patient's eligibility, testing, treatment, administration setting, and follow-up. Call 911 for a medical emergency. Contact Nao Medical with a question or correction.
(917) 310-3371